How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/unresectable-or-metastatic-melanoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Unresectable or metastatic melanoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unresectable or metastatic melanoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Unresectable or metastatic melanoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
OPDUALAG	RELATLIMAB-RMBW	BRISTOL MYERS SQUIBB	Programmed Death Receptor-1 Blocking Antibody [EPC]	Lymphocyte activation gene 3 protein
Opdualag	Opdualag	Australian & New Zealand Children's Haematology/Oncology Group		Lymphocyte activation gene 3 protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Australian & New Zealand Children's Haematology/Oncology Group · 1 drug in Unresectable or metastatic melanoma
BRISTOL MYERS SQUIBB · 1 drug in Unresectable or metastatic melanoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unresectable or metastatic melanoma:

Cite this brief

Drug Landscape (2026). Unresectable or metastatic melanoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-or-metastatic-melanoma. Accessed 2026-06-10.

Unresectable or metastatic melanoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing